Novartis AG (Novartis AG) Construction In Progress

: $1,213 Mil (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

Novartis AG's quarterly construction in progress stayed the same from Jun. 2023 ($0 Mil) to Sep. 2023 ($0 Mil) but then increased from Sep. 2023 ($0 Mil) to Dec. 2023 ($1,213 Mil).

Novartis AG's annual construction in progress declined from Dec. 2021 ($1,508 Mil) to Dec. 2022 ($1,184 Mil) but then increased from Dec. 2022 ($1,184 Mil) to Dec. 2023 ($1,213 Mil).

Novartis AG Construction In Progress Historical Data

The historical data trend for Novartis AG's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

1,350.00

1,248.00

1,508.00

1,184.00

1,213.00

Novartis AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Construction In Progress	Get a 7-Day Free Trial															1,184.00	-	-	-	1,213.00

Novartis AG Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Novartis AG (Novartis AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (NYSE:NVS) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

NVSEF:USA NVS N:Mexico NOVNz:UK 0QLR:UK NOTA:Germany NOTA:Germany NOVNEE:Switzerland NOVN:Switzerland N1VS34:Brazil NVS:Argentina

Address

Lichtstrasse 35, Basel, CHE, 4056

Website

https://www.novartis.com

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.